Scarica l'app Stockscreener
0.9782
2.97%
0.0282
Dopo l'orario di chiusura:
.97
-0.0082
-0.84%
Mira Pharmaceuticals Inc Borsa (MIRA) Ultime notizie
MIRA PHARMACEUTICALS (MIRA) director granted 50,000 stock options award - Stock Titan
MIRA Pharmaceuticals (MIRA) grants director 50,000 stock options at $0.94 - Stock Titan
MIRA Pharmaceuticals grants director 50,000 stock options | MIRA Insider Trading - Stock Titan
MIRA Pharmaceuticals Inc. (MIRA) Edges Higher: Navigating Key Levels in a Volatile SectorGolden Cross - newsline.com
MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer - The Globe and Mail
MIRA PHARMACEUTICALS (MIRA) CFO Andriy Mushak listed as insider in Form 3 - Stock Titan
Mira Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com - Investing.com Nigeria
Mira Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com
Mira PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView
MIRA appoints Andriy Mushak as fractional CFO as Alan Weichselbaum departs - TradingView
Mira Pharmaceuticals (NASDAQ: MIRA) hires fractional CFO via LMAM - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
MIRA Pharmaceuticals Holds Steady at $1.0 as Key Support and Resistance TestedLinear Regression - newsline.com
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 - ACCESS Newswire
MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline - TipRanks
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1SEC Filing - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) consolidates worldwide exclusive rights to MIRA-55 and SKNY-1 - Stock Titan
Experimental obesity and chronic pain drugs now under MIRA's global control - Stock Titan
MIRA Pharmaceuticals Faces Subdued Sentiment as Stock Dips Toward Key SupportAccumulation Line - newsline.com
MIRA News | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Pharmaceuticals Inc. (MIRA) Slips 8.66% to $1.05 as Technicals Test Key SupportRevenue Growth Stocks - The Legal Advocate
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN - Black Hills Pioneer
MIRA Pharmaceuticals Q3 2025 Earnings: EPS Beats Estimates Amid Narrowing Losses; Stock DeclinesEarnings Call Q&A - newsline.com
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide - Investing.com UK
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide By Investing.com - Investing.com Nigeria
MIRA Expands Global Ketamir-2 License for Clinical Development - TipRanks
Mira Pharmaceuticals enters into amendment no 1 to exclusive license agreement with Miralogx - marketscreener.com
MIRA Pharmaceuticals (MIRA) expands Ketamir-2 license to worldwide IP rights - Stock Titan
Experimental oral chemo nerve damage drug gets IP boost in 10 countries - Stock Titan
MIRA Pharmaceuticals Edges Higher, Consolidating Near Key Resistance at $1.04AAII Bearish - newsline.com
MIRA Pharmaceuticals Inc. (MIRA) Nears Support After Marginal DeclineRetracement Entry - The Legal Advocate
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Season Outlook - The Legal Advocate
MIRA Q3 2025 Earnings: Narrowed Loss Surpasses Expectations Amid No RevenueCFO Commentary Report - The Legal Advocate
MIRA Stock Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Pharmaceuticals (MIRA) Q3 2025 Earnings: Why the Beat MattersRising Community Picks - Newser
What MIRA Pharmaceuticals (MIRA)'s +1.35% Jump Means for Investors 2026-05-18Sentiment Extreme - The Legal Advocate
What's going on with MIRA Pharma stock Tuesday? - MSN
Should You Sell MIRA Pharmaceuticals (MIRA) After -1.24% Drop? 2026-05-15Golden Cross - Newser
MIRA Pharmaceuticals (MIRA) Delivers Q3 2025 Beat — EPS $-0.06 vs $-0.08 ExpectedAnalyst Stock Picks - Newser
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 - Black Hills Pioneer
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MIRA Pharmaceuticals (MIRA) posts Q1 2026 loss and warns on going concern - Stock Titan
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 - Investing.com UK
Mira Pharmaceuticals stock gains on Phase 1 trial results By Investing.com - Investing.com South Africa
Mira Pharmaceuticals stock gains on Phase 1 trial results - Investing.com
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 By Investing.com - Investing.com Canada
Chemo nerve damage has no FDA drugs—MIRA advances new Ketamir-2 pill - Stock Titan
MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results - TipRanks
MIRA (MIRA) posts positive Phase 1 data and DEA decision on Ketamir-2 - Stock Titan
0.46%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):